AI Article Synopsis
- Hepatitis B and C infections are common among HIV-infected individuals, especially in Southeast Asia, where rates of coinfection range from 3.2-11%.
- Most hepatitis B cases involve genotype C, while hepatitis C in Thailand is mainly genotype 3 linked to intravenous drug use, and in Vietnam, it’s mostly genotype 6.
- Treatment options are limited, with only HBV treatment being freely available, and there's a need for better hepatitis screening and cost-effective HCV treatment incorporated into national health programs.
Article Abstract
Hepatitis B and C infections are prevalent among HIV-infected individuals with different epidemiologic profiles, modes of transmission, natural histories, and treatments. Southeast Asian countries are classified as "highly prevalent zones," with a rate of hepatitis B and C coinfection in people living with HIV/AIDS of approximately 3.2-11%. Majority of hepatitis B coinfection is of genotype C. Most of the patients infected with hepatitis C in Thailand have genotype 3 which is significantly related to intravenous drug use whereas, in Vietnam, it is genotype 6. The options for antiretroviral drugs are limited and rely on global funds and research facilities. Only HBV treatment is available for free through the national health scheme. Screening tests for HBV and HCV prior to commencing antiretroviral treatment are low. Insufficient concern on hepatitis-virus-related liver malignancy and long-term hepatic morbidities is noted. Cost-effective HCV treatment can be incorporated into the national health program for those who need it by utilizing data obtained from clinical research studies. For example, patients infected with HCV genotype 2/3 with a certain IL-28B polymorphism can be treated with a shorter course of interferon and ribavirin which can also help reduce costs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318196 | PMC |
| http://dx.doi.org/10.1155/2012/948059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preadmission VACS Index as a Predictor of Hospital Acute Kidney Injury in People with HIV.
J Acquir Immune Defic Syndr
December 2024
Division of Nephrology, Albert Einstein College of Medicine, Montefiore Health System, Bronx, NY.
Background: The Veterans Aging Cohort Study (VACS) Index is a summary measure of routinely obtained clinical variables that predicts numerous health outcomes. Since there are currently no tools to predict acute kidney injury (AKI) in persons with HIV (PWH), we investigated the association of preadmission VACS Index with hospital AKI in PWH.
Methods: We conducted an observational study of PWH hospitalized in a New York City health system between 2010-2019.
Seroprevalence of Hepatitis E Virus Among Schistosomiasis mansoni Patients Residing in Endemic Zone in Brazil.
Trop Med Infect Dis
December 2024
Postgraduate Program in Tropical Medicine, Center of Medical Sciences, Universidade Federal de Pernambuco (UFPE), Recife 50670-420, PE, Brazil.
The occurrence of hepatitis E virus (HEV) in patients with Schistosomiasis mansoni (SM) is still poorly understood in Brazil. The objective of this study was to estimate the seroprevalence of anti-HEV IgG in patients with SM and its association with the periportal fibrosis (PPF), assessed by serum markers and ultrasound criteria. This cross-sectional study was carried out in an endemic area in Pernambuco, Brazil, with schistosomal patients who underwent coproscopic survey.
View Article and Find Full Text PDFEffect of depressive symptoms on health services utilization in the HIV and hepatitis C co-infected population in Canada.
AIDS Care
December 2024
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
Depression is common among people living with HCV and HIV, which contributes to health services utilization (HSU). It is unknown whether successful HCV treatment affects this. We examined depressive symptoms and HSU in people co-infected with HIV-HCV and their association with sustained virologic response (SVR) during the direct-acting antiviral era.
View Article and Find Full Text PDFInteraction Between Hepatitis B, Hepatitis C and Alcohol in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
J Viral Hepat
January 2025
Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
The objective of this report is to provide clarification on the interaction among hepatitis B virus (HBV), hepatitis C virus (HCV) and alcohol in the development of hepatocellular carcinoma (HCC). A systematic search was performed in PubMed, Web of Science and Scopus databases up to July 18, 2023. The inclusion criteria involved observational studies that examined the relationship between HBV, HCV, alcohol use and the development of HCC.
View Article and Find Full Text PDFHost-Targeting Antivirals for Chronic Viral Infections of the Liver.
Antiviral Res
December 2024
Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany; German Centre for Infection Research (DZIF), External Partner Site, Bochum, Germany. Electronic address:
Infection with one or several of the five known hepatitis viruses is a leading cause of liver disease and poses a high risk of developing hepatocellular carcinoma upon chronic infection. Chronicity is primarily caused by hepatitis B virus (HBV) and hepatitis C virus (HCV) and poses a significant health burden worldwide. Co-infection of chronic HBV infected patients with hepatitis D virus (HDV) is less common but is marked as the most severe form of chronic viral hepatitis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!